Financial Wire

ATS Maintained at Buy at Stifel Canada; Price Target Kept at C$52.00

-- Stifel Canada on Monday maintained its buy rating on the shares of ATS (ATS.TO) and its C$52.00 price target as it sees little impact from a fresh round of U.S. tariffs.

"We view the expanded Section 232 tariffs on steel and aluminum as not having a material impact to ATS. ATS is a global end-to-end automation provider (Design + Build + Service) of high-performance robotic systems with valuable end-market exposure, including Life Sciences (~60% of sales). Approximately 20% of ATS' revenue is associated with flows into the U.S. from Canada and Europe with a large proportion currently exempt under USMCA with risk mitigation underway, including substantial expansion at Chicago facilities. Although the tariff situation remains fluid and Section 232 raises questions with certain other companies impacted, we believe ATS' global operations, contract protections in-place and the long-term nature of mission-critical projects (12-18 months) provide ample flexibility to navigate at this stage. We are also encouraged by recent insider buying, including new (Jan. start) CEO, Doug Wright and ATS' largest shareholder, Mason Capital at ~C$41/share, near current levels," analyst Justin Keywood wrote.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $45.03, Change: $+0.22, Percent Change: +0.49%

Related Articles

Australia

Axcelis Technologies Shares Rise After Upgrade From B. Riley

Axcelis Technologies (ACLS) shares were up 8.6% in afternoon trading on Monday after B. Riley upgraded the company's stock to buy from neutral and raised the price target to $150 from $91.Trading volume stood at around 809,000 shares, roughly the same number as the stock's daily average.Price: $128.52, Change: $+9.79, Percent Change: +8.25%

$ACLS
Australia

Argus Cuts Abbott Laboratories' Price Target to $125 From $140

Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $120.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $96.06, Change: $-0.75, Percent Change: -0.77%

$ABT
Mining & Metals

NevGold Upsizes Brokered Private Placement Financing to up to Around C$42.2 Million

NevGold (NAU.V) on Monday said it is upsizing best-efforts private placement of shares to $42.2 million, up from its original $25-million target.The company said it will now look to place 22.2 million shares priced of C$1.90 each.The company plans to use proceeds for advancing its Limousine Butte antimony-gold project in Nevada, the Nutmeg Mountain gold project in Idaho, and for working capital and general corporate purposes.The company's shares were last seen up $0.04 to $2.14 on the TSX Venture Exchange.Price: $2.16, Change: $+0.06, Percent Change: +2.86%

$NAU.V